PepHaūs Review
Best for: shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide
PepHaūs is a telehealth pharmacy offering compounded GLP-1 weight-loss treatment — semaglutide from $152/mo and tirzepatide from $246/mo — prescribed by U.S.-licensed providers and shipped from 503A compounding pharmacies. Its pitch is all-inclusive pricing: the medication, medical visit, and shipping are bundled into one cost, with an extra 15% off on quarterly plans. It also offers NAD+, sermorelin, and glutathione alongside weight loss.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
PepHaūs is a solid telehealth option with balanced features and pricing.
How we scored PepHaūs
Each dimension is scored algorithmically from PepHaūs’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
7.8/10At $152/mo, PepHaūs runs about 10% below the $169 median for GLP-1 providers.
Effectiveness25%
7.8/10PepHaūs offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.1/10Online intake and platform experience — consult included in the price; 6 platform features disclosed.
Trust & Safety15%
8.5/10Key details fully confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy (last checked 2026-06-16).
Accessibility10%
8.0/10PepHaūs treats patients in all 50 states.
Support10%
5.6/10PepHaūs provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this PepHaūs review
Last checked 2026-06-16- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: high.
GLP-1 medications PepHaūs offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide | compounded | $152 |
| Compounded Tirzepatide | compounded | $246 |
What we like
- All-inclusive pricing — medication, medical visit, and shipping bundled into one cost
- Compounded semaglutide from $152/mo (quarterly) and tirzepatide from $246/mo
- LegitScript-certified (#50233613); 503A-compounded medication
- Ships to all 50 states from U.S.-licensed 503A pharmacies
- Quick online intake with 24-hour provider review
Watch-outs
- Compounding pharmacy partners aren't named on the marketing site
- Pricing is customized per patient, so your final cost can vary from the advertised 'from' rates
- No published individual clinician or medical-director names
- Newer multi-vertical brand (also NAD+, sermorelin, glutathione) with a limited weight-loss track record
Is PepHaūs worth it? Our verdict
PepHaūs positions itself around one thing: shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide. It runs $152/month — toward the affordable end of the market. It treats patients in all 50 states, so access isn't a barrier.
How much PepHaūs actually costs
- Compounded semaglutide — $152/month
- Compounded tirzepatide — $246/month
That puts PepHaūs below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Medications: what PepHaūs prescribes
PepHaūs prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who PepHaūs is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
- live anywhere in the US and want guaranteed access.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
PepHaūs treats patients in all 50 states, and dispenses through an accredited compounding pharmacy. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
PepHaūs earns its place on the shortlist mainly on price: at $152/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
Ready to start with PepHaūs?
Starting at $152/month. See current pricing and start your free consultation.
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this PepHaūs review:
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to PepHaūs
Editorial score · methodology
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with PepHaūs?
Starting at $152/month. See current pricing and start your free consultation.